Timothy Kuzel, MD, Oncology, Chicago, IL, Rush University Medical Center

TimothyKuzelMDFACP

Oncology Chicago, IL

Genitourinary Oncology, Hematologic Oncology

Chief, Division of Hematology/Oncology and Cell Therapy, Rush University Medical School

Dr. Kuzel is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kuzel's full profile

Already have an account?

Education & Training

  • McGaw Medical Center of Northwestern University
    McGaw Medical Center of Northwestern UniversityFellowship, Hematology, 1987 - 1990
  • McGaw Medical Center of Northwestern University
    McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1984 - 1987
  • University of Michigan Medical School
    University of Michigan Medical SchoolClass of 1984
  • University of MichiganBA, Biomedical Sciences, Cum Laude, 1978 - 1981
  • University of MichiganB.S., Biomedical Sciences, 1981

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1984 - 2023
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Chicago Magazine: Top Doctors Castle Connolly, 2008, 2010, 2012, 2014, 2016, 2018, 2020
  • America's Top Doctors Castle Connolly, 2008-2017
  • America's Top Doctors for Cancer Castle Connolly, 2007-2017
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The efficacy of lenvatanib and everolimus in Chromophobe-type non-Clear Cell Renal Cell Cancer: A case report and Literature review  
    Schwartz C, Pfanzelter N, Kuzel TM, Clin Genitourin Cancer, 1/25/2017
  • A Phase II Trial of Dasatinib in Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanoma: A trial of the ECOG-ACRIN Cancer Res...  
    Kevin Kalinsky, Sandra Lee, KristaRubin, Donald P. Lawrence, Anthony J. Iafrarte, Darell R. Borger, Kim A. Margolin, Mario M. Leitao, Jr, Ahmad A. Tarhini, Henry B. Ko..., Cancer, 1/23/2017
  • Exogenous IL-33 restores dendritic cell activation and maturation in established cancer  
    Dominguez D, Ye C, Geng Z, Chen S, Fan J, Qin L, Long A, Wang A, Zhang Z, Zhang Y, Fand D, Kuzel TM, Bin Zhang, Journal of Immunology, 1/1/2017
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-HodgkinÍs Lymphoma
    Timothy M. Kuzel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Comparing association of trans rectal ultrasound prostate weight with actual prostate weight obtained after radical prostatectomy after adjustment for other prognostic...
    Helenowski, I.B., Jovanovic, B.D., Gurley, M.J., Leikin, R.G., Catalona W.J., Rosten, A.B., Kuzel, T.M., Proceedings of the American Physical Society, New Orleans, LA, 1/1/2017
  • Updated Analyses of the International, Open-label, Randomized, Phase 3 ALCANZA Study: Longer-term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate o...
    Julia Scarisbrick, Steven M. Horwitz, Reinhard Dummer, Madeleine Duvic, Youn H. Kim, Jan Walewski, Sean Whittaker, Pietro Quaglino, Pier Luigi Zinzani, Pascal Wolter, ..., Proceedings of the American Society of Hematology, Atlanta, GA, 1/1/2017
  • Join now to see all

Lectures

  • Updated Analyses of the International, Open-label, Randomized, Phase 3 ALCANZA Study: Longer-term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate o... 
    London, United Kingdom - 1/13/2017
  • Immunotherapy of Cancer 
    1/1/2012
  • A phase 2 mutli-center, randomized, open-label study of two dose levels of IMO-2055 in Patients with metastatic or recurrent Renal Cell Carcinoma. 
    1/1/2009
  • Join now to see all

Other

  • The use of Gemcitabine in metastatic urothelial transitional cell cancer 
    Kuzel TM and Stadler WM, Lilly Monograph
    1/1/1996
  • Book Review of --Atkins MB and Mier JW. Therapeutic Applications of Interleukin-2. 
    Kuzel TM, Doody's Health Sciences Book Review Annual
    1/1/1993
  • Interferons: Basic Principles and Clinical Applications. 
    Kuzel TM. Book Review of --Estrov Z, Kurzock R, and Talpaz M, Doody's Health Sciences Book Review Annual
    1/1/1993

Press Mentions

  • Rush Earns ASCO QOPI Certification for High-Quality Cancer Care
    Rush Earns ASCO QOPI Certification for High-Quality Cancer CareSeptember 5th, 2019
  • Personalized Vaccine Helps Patients Fight Ovarian Cancer
    Personalized Vaccine Helps Patients Fight Ovarian CancerApril 12th, 2018
  • Vaccine Giving New Hope in Fight Against Cancer
    Vaccine Giving New Hope in Fight Against CancerFebruary 9th, 2018
  • Join now to see all

Professional Memberships

Hospital Affiliations